LI2DAY

Li2Day is a clinical-stage biotechnology company based in Beijing, China, that focuses on the development of long-acting injectable (LAI) formulations for central nervous system disorders. The company utilizes a proprietary microsphere technology platform to deliver sustained-release versions of established psychiatric medications, such as risperidone and paliperidone. Its lead candidate, LI2DAY-001, is currently in late-stage clinical trials for the treatment of schizophrenia, aiming to improve patient adherence and therapeutic consistency. By reducing the frequency of administration, Li2Day's products are designed to lower the risk of relapse and improve the quality of life for patients with chronic mental health conditions. The company is backed by prominent venture capital firms and continues to expand its pipeline into other neurological indications.